Syam Chodagiri currently serves as the Executive Director and Head of Digital Technology & Innovation at Amgen, where he leverages over two decades of extensive experience in the biotechnology and pharmaceutical sectors to drive transformative technology initiatives. His role is pivotal in shaping Amgen's digital...
Syam Chodagiri currently serves as the Executive Director and Head of Digital Technology & Innovation at Amgen, where he leverages over two decades of extensive experience in the biotechnology and pharmaceutical sectors to drive transformative technology initiatives. His role is pivotal in shaping Amgen's digital landscape, focusing on the integration of advanced technologies such as Generative AI (GenAI) to enhance product and process development. Syam is at the forefront of crafting innovative digital data strategies that not only streamline operations but also align with the company's overarching business objectives.
At Amgen, Syam has spearheaded key projects that encompass GxP clinical and commercial manufacturing, ensuring that the implementation of cutting-edge technologies adheres to stringent regulatory standards. His expertise in governance and business process optimization has been instrumental in navigating complex mergers and acquisitions, enabling seamless transitions and fostering synergies across diverse teams. As a visionary thought leader, he is committed to cultivating a culture of innovation, empowering his teams to explore new avenues for digital transformation.
Syam’s proficiency in IT executive management and product marketing, combined with his strategic approach to digital marketing and business planning, positions him as a catalyst for change within the organization. His passion for harnessing technology to drive impactful business outcomes is evident in his collaborative leadership style, which inspires cross-functional teams to embrace digital advancements. As he continues to lead Amgen into the future, Syam remains dedicated to leveraging technology to enhance patient outcomes and drive sustainable growth in the biopharma industry.
